https://www.patientcareonline.com/view/abelacimab-receives-fast-track-designation-from-fda-for-prevention-of-stroke-systemic-embolism-in-patients-with-atrial-fibrillation
0
0
9/10/22 at 7:41am
Organization
Patientcareonline.com
Author
Sydney Jennings
42 words
0
Comments
Abelacimab is a dual-acting, fully human monoclonal antibody that selectively targets both factor XI and factor XIa with high affinity.
You are the first to view
Create an account
or login to join the discussion